DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

被引：389
作者：
O'Connor, J. P. B.
Jackson, A.
Parker, G. J. M.
Jayson, G. C.
机构：
[1] Univ Manchester, Imaging Sci & Biomed Engn, Manchester M13 9PT, Lancs, England
[2] Christie Hosp, Canc Res UK Dept Med Oncol, Manchester M20 4BX, Lancs, England
来源：
BRITISH JOURNAL OF CANCER | 2007年 / 96卷 / 02期
基金：
英国医学研究理事会;
关键词：
angiogenesis inhibitors; biomarkers; clinical trials; dynamic contrast; enhanced magnetic resonance imaging; image analysis;
D O I：
10.1038/sj.bjc.6603515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T-1-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.
引用
收藏
页码：189 / 195
页数：7
相关论文
共 43 条
  • [1] Cellular abnormalities of blood vessels as targets in cancer
    Baluk, P
    Hashizume, H
    McDonald, DM
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) : 102 - 111
  • [2] Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement
    Buonaccorsi, Giovanni A.
    Roberts, Caleb
    Cheung, Sue
    Watson, Yvonne
    O'Connor, James P. B.
    Davies, Karen
    Jackson, Alan
    Jayson, Gordon C.
    Parker, Geoff J. M.
    [J]. ACADEMIC RADIOLOGY, 2006, 13 (09) : 1112 - 1123
  • [3] Conrad C, 2004, J CLIN ONCOL, V22, p110S
  • [4] Dowlati A, 2002, CANCER RES, V62, P3408
  • [5] Drevs J, 2005, J CLIN ONCOL, V23, p192S
  • [6] Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily
    Eder, JP
    Supko, JG
    Clark, JW
    Puchalski, TA
    Garcia-Carbonero, R
    Ryan, DP
    Shulman, LN
    Proper, J
    Kirvan, M
    Rattner, B
    Connors, S
    Keogan, MT
    Janicek, MJ
    Fogler, WE
    Schnipper, L
    Kinchla, N
    Sidor, C
    Phillips, E
    Folkman, J
    Kufe, DW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3772 - 3784
  • [7] Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126
    Evelhoch, JL
    LoRusso, PM
    He, ZQ
    DelProposto, Z
    Polin, L
    Corbett, TH
    Langmuir, P
    Wheeler, C
    Stone, A
    Leadbetter, J
    Ryan, AJ
    Blakey, DC
    Waterton, JC
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3650 - 3657
  • [8] Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging
    Galbraith, SM
    Maxwell, RJ
    Lodge, MA
    Tozer, GM
    Wilson, J
    Taylor, NJ
    Stirling, JJ
    Sena, L
    Padhani, AR
    Rustin, GJS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2831 - 2842
  • [9] Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging
    Galbraith, SM
    Rustin, GJS
    Lodge, MA
    Taylor, NJ
    Stirling, JJ
    Jameson, M
    Thompson, P
    Hough, D
    Gumbrell, L
    Padhani, AR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3826 - 3840
  • [10] HECHT JR, 2005, J CLIN ONCOL, V23, P3
12345